Zovaglutide

Zovaglutide increases normoglycemia in humans (93.5%, 96.4%, 90.5% and 100.0% vs. 22.2%).

“The proportions of participants achieved HbA1c<5.7% at week 24 in zovaglutide 80 mg Q4W group, 160 mg Q4W group, 80 mg Q2W group and 160 mg Q2W group were greater than in placebo group (93.5%, 96.4%, 90.5% and 100.0% vs. 22.2%).”

Human trialin adults with overweight or obesity and prediabetes24 weeks

Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis

ADA Scientific Sessions 2026 abstract·5 Jun 2026

Zovaglutide decreases body weight in humans (-10.8% to -12.8% vs. -0.8%, p<0.0001).

“The percentage changes from baseline in weight in zovaglutide groups at week 24 were significantly greater than in placebo group (-10.8%, -12.8%, -12.9% and -12.8% vs. -0.8%, all p values<0.0001).”

Human trialin adults with overweight or obesity and prediabetes24 weeks

Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis

ADA Scientific Sessions 2026 abstract·5 Jun 2026